JCM Figure table search 04
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Morace, G.
Right arrow Articles by Pitzurra, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Morace, G.
Right arrow Articles by Pitzurra, L.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, August 2002, p. 2953-2958, Vol. 40, No. 8
0095-1137/02/$04.00+0     DOI: 10.1128/JCM.40.8.2953-2958.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

Multicenter Comparative Evaluation of Six Commercial Systems and the National Committee for Clinical Laboratory Standards M27-A Broth Microdilution Method for Fluconazole Susceptibility Testing of Candida Species

G. Morace,1* G. Amato,2 F. Bistoni,3 G. Fadda,4 P. Marone,5 M. T. Montagna,6 S. Oliveri,7 L. Polonelli,8 R. Rigoli,9 I. Mancuso,10 S. La Face,10 L. Masucci,4 L. Romano,4 C. Napoli,6 D. Tatò,6 M. G. Buscema,7 C. M. C. Belli,2 M. M. Piccirillo,2 S. Conti,8 S. Covan,8 F. Fanti,8 C. Cavanna,5 F. D'Alò,3 and L. Pitzurra3

Istituto di Microbiologia, Università degli Studi di Milano, Milan,1 Laboratorio di Patologia Clinica, Azienda Ospedaliera di Rilievo Nazionale, Cardarelli, Naples,2 Dipartimento di Medicina Sperimentale e Scienze Biochimiche, Sezione di Microbiologia, Università degli Studi di Perugia, Perugia,3 Istituto di Microbiologia, Università Cattolica del Sacro Cuore, Rome,4 Laboratorio di Batteriologia e Micologia, Istituto di Ricovero e Cura a Carattere Scientifico, San Matteo, Pavia,5 Dipartimento di Medicina Interna e Medicina Pubblica, Sezione di Igiene, Università degli Studi di Bari, Bari,6 Dipartimento di Scienze Microbiologiche e Scienze Ginecologiche, Sezione di Microbiologia, Università degli Studi di Catania, Catania,7 Dipartimento di Patologia e Medicina di Laboratorio, Sezione di Microbiologia, Università degli Studi di Parma, Parma,8 Laboratorio di Microbiologia, Ospedale Ca' Foncello, Treviso,9 Pfizer Italia SpA, Rome, Italy,10

Received 20 February 2002/ Returned for modification 18 April 2002/ Accepted 27 May 2002

Fluconazole susceptibility among 800 clinical Candida isolates (60% C. albicans) and two control strains (C. krusei ATCC 6258 and C. parapsilosis ATCC 22019) was tested with the NCCLS M27-A method (gold standard) and six commercial products (Candifast, disk, Etest, Fungitest, Integral System Yeasts, and Sensititre YeastOne). Results were classified as susceptible, susceptible-dose dependent, or resistant using M27-A breakpoints or, for Fungitest, Integral System Yeasts, and Candifast, as susceptible, intermediate, or resistant, according to the manufacturers' instructions. Concordance with NCCLS M27-A results was analyzed with the {chi}2 test. Intra- and interlaboratory reproducibility was also evaluated. NCCLS M27-A (90.1%), Etest (93.1%), Sensititre YeastOne (93.1%), disk (96.7%), Fungitest (92.6%), Integral System Yeasts (40.6%), and Candifast (6.0%) classified the indicated percentages of C. albicans isolates as susceptible. Among non-C. albicans strains, the percentages of susceptible isolates were as follows: NCCLS M27-A, 74.0%; Etest, 83.8%; Sensititre YeastOne, 64.1%; disk, 60.6%; Fungitest, 76.6%; Integral System Yeasts, 28.3%; and Candifast, 27.4%. All methods except Candifast and Integral System Yeasts showed good agreement with NCCLS M27-A results for both C albicans and non-C. albicans isolates. Intralaboratory reproducibility was excellent for NCCLS M27-A, Etest, Sensititre YeastOne, disk, and Fungitest (88 to 91%). Similar results emerged from the interlaboratory reproducibility evaluation. Our findings indicate that some commercial methods can be useful for fluconazole susceptibility testing of clinical Candida isolates. Those characterized by a lack of medium standardization and/or objective interpretative criteria should be avoided. Particular caution is necessary when testing is being done for clinical and epidemiological purposes.


* Corresponding author. Mailing address: Istituto di Microbiologia, Università degli Studi di Milano, Via Pascal, 36-20133 Milan, Italy. Phone: 39 02 50315065. Fax: 39 02 50315068. E-mail: giulia.morace{at}unimi.it.


Journal of Clinical Microbiology, August 2002, p. 2953-2958, Vol. 40, No. 8
0095-1137/02/$04.00+0     DOI: 10.1128/JCM.40.8.2953-2958.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.




This article has been cited by other articles:




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Antimicrob. Agents Chemother. Clin. Microbiol. Rev.
Clin. Vaccine Immunol. ALL ASM JOURNALS

Copyright © 2002 by the American Society for Microbiology. All rights reserved.